Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2026)
Spero Therapeutics (SPRO) reported Other Non Operating Income of -$1000.0 for Q1 2026, down 200.0% on a YoY basis from $1000.0 in Q1 2025, and down 150.0% quarter-over-quarter from $2000.0 in Q3 2025.
Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2026) Analysis & Trends
Spero Therapeutics has reported Other Non Operating Income for 11 years, with the latest figure at -$1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 200.0% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at $5000.0 (down 93.33% YoY), and the FY2025 full-year result was $7000.0, down 88.33% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$1000.0, down from $2000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $995000.0 in Q2 2022, with the low at -$193000.0 in Q1 2022.
- Historically, Other Non Operating Income has averaged $60687.5 across 5 years, with a median of $0.0 in 2024.
- The largest YoY upside for Other Non Operating Income was 3200.0% in 2024 against a maximum downside of 600.0% in 2024.
- Spero Therapeutics' Other Non Operating Income stood at $141000.0 in 2022, then slumped by 97.87% to $3000.0 in 2023, then soared by 3200.0% to $99000.0 in 2024, then plunged by 97.98% to $2000.0 in 2025, then slumped by 150.0% to -$1000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1000.0 (Q1 2026), $2000.0 (Q3 2025), and $4000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Spero Therapeutics | 129.74 Mn | 73.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | 995,000.00 |
| Mar 31, 2022 | -193,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Mar 31, 2021 | -118,000.00 |
| Dec 31, 2020 | 162,000.00 |
| Sep 30, 2020 | 55,000.00 |